Size is one of the decisive characteristics of liposomes for advanced chemotherapy of tumors. Larger sized liposomes are effectively taken up by the reticuloendothelial system (RES) and cleared from ...
A new option is now available for patients with metastatic pancreatic cancer who have previously been treated with gemcitabine-based chemotherapy. The US Food and Drug Administration (FDA) has just ...
Phase II Trial of Docetaxel, Cisplatin, Fluorouracil, and Leucovorin as Induction for Squamous Cell Carcinoma of the Head and Neck PURPOSE: Stealth (ALZA Corporation, Palo Alto, CA) liposomal drug ...
Phase II, Single-Arm Trial of Induction and Concurrent Vismodegib With Curative-Intent Radiation Therapy for Locally Advanced, Unresectable Basal Cell Carcinoma Patients with SCLC and progression on ...
Global market grows at 6.3% CAGR through 2033 as demand rises for safer, targeted chemotherapy treatments worldwide.
Three reviewers (LA, FS and SN) independently examined the collected studies in two steps. The first step consisted of critically reading titles, keywords and abstracts. In the second step, the full ...
A newly described small molecule inhibitor called AOH-1996 targets a cancer-associated isoform of PCNA (caPCNA), leading to a very broad therapeutic window.
A research team led by the Medical University of Vienna, the HUN-REN Research Centre for Natural Sciences and the Eötvös Loránd University in Budapest has developed a groundbreaking new ...
Ewing, NJ's Celator Pharmaceuticals has raised $40.6 million by issuing 4.6 million additional shares of the company's common stock for $9.50 a share. That included 600,000 shares issued because the ...
At the 30th Annual Congress of the European Society for Gene and Cell Therapy in Brussels this week, researchers presented both preclinical and clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results